Pleximmune™
Acute cellular rejection occurs early or late after liver or intestine transplantation in children. This is the most common type of rejection and it happens when T-lymphocytes from the recipient directly attack and destroy cells in the transplanted liver or intestine. Acute cellular rejection is usually suspected because of the dysfunction of the transplanted organ. Dysfunction is suggested by elevated liver function tests which can be measured in the blood of a liver recipient. For intestine transplant rejection, the only evidence may be high stool output, however, high stool output can also occur with an infection. Elevated liver function tests can also be seen with infection and mechanical blockage. A “for cause” biopsy is needed to confirm rejection. These biopsies can cause bleeding or perforation and, sometimes, may not affirm a rejection. These side effects can be especially harmful in children. Acute cellular rejection can also occur without clinical evidence of organ dysfunction, especially if immunosuppression is suboptimal. Surveillance biopsies are performed at predetermined intervals to detect this type of ‘silent’ rejection and assess immunosuppression.
An FDA-approved blood test, PleximmuneTM measures the risk of acute cellular rejection after liver or intestine transplantation in children and young adults less than 21 years of age.
Pleximmune™ is an FDA-approved blood test that measures the risk of acute cellular rejection after liver or intestinal transplantation in children and young adults up to 21 years of age. The test measures whether recipient lymphocytes called T-cytotoxic memory cells show increased anti-donor activity. This activity is measured after stimulating lymphocytes from the recipient with donor or donor-like cells. This then determines whether the anti-donor activity has increased or decreased, it is then compared with activity toward non-donor (reference) cells. Knowledge about the likelihood of acute cellular rejection can be combined with clinical information to develop a treatment plan by:
#
CATEGORY
DETAILS
1
Assay Category
Whole blood collected in a sodium heparin (green-top) tube.
2
Intended Use
5 mL in children.
3
Methodology
30 hours at room temperature from the time of phlebotomy.
4
Test Report
5 mL in children.
5
Test Readout
Index of Rejection (IR), the IR is the ratio of the recipient T-cytotoxic memory cell activity toward donor or donor-like cells and reference cells.
6
Reference Range
The IR is an absolute number with a range of less than 1.15 to 1.15 or greater.
7
Test Interpretation
An IR of 1.15 or more indicates an increased likelihood of acute cellular rejection.
Purpose
Knowledge about the risk of rejection can be combined with available clinical data to plan additional treatment for your patient.
Rationale
Intended Use
To assess the risk of acute cellular rejection after liver or intestine transplantation in children.
Procedure
Performance
The Pleximmune™ test is performed in Plexision's CLIA- approved laboratory and
Benefits
Determining whether rejection is likely is important in deciding
Knowledge about the likelihood of rejection from the PleximmuneTM test can be combined with other clinical data by your healthcare provider to make clinical decisions.
Insurance Coverage
Plexision will bill the patient's insurance plan and work directly with the insurer for payment. Plexision will assist with the cost of Pleximmune™, if there is no insurance coverage. For additional information, call 1.855.753.9474 or email info@plexision.com
Sample & Handling
#
CATEGORY
DETAILS
1
Sample Type
Whole blood collected in a sodium heparin (green-top) tube.
2
Volume
5 mL in children.
3
Transport Conditions
Ship priority overnight, at room temperature. Sample must get to Plexision within 30 hours of phlebotomy.
4
Specimen Stability
30 hours at room temperature from the time of phlebotomy.
5
Sample Discard Criteria
How To Order
#
CATEGORY
DETAILS
1
Test Brochure
View and download the product brochure here.
2
Ordering Tests
Please complete this form, print, and fax to 412-224-2776.
What is Pleximmune™?
PleximmuneTM is a blood test that helps your healthcare provider determine the risk of rejection after liver or intestine transplantation in children and young adults < 21 years old.
Who can benefit?
Liver or intestine transplant recipients < 21 years old can benefit from the PleximmuneTM test.
What is involved in the Pleximmune™ test?
The PleximmuneTM test must be ordered by your healthcare provider. The test requires a blood sample measuring a teaspoon. This sample is to be shipped overnight to Plexision’s laboratory for analysis. Results are sent to your healthcare provider within a day of your sample arriving at the laboratory. Your healthcare provider will help you understand the results.
How long does it take to get results of the Pleximmune™ test?
Results are ready within 30 hours after the laboratory receives the blood sample.
How does the Pleximmune™ test work?
The point of using dummy text for your paragraph is that it has a more-or-less normal distribution of letters. making it look like readable English.
How do I interpret the test results?
The results are reported as an Immunoreactivity Index or IR. An IR less than 1.15 implies a decreased risk of rejection. An IR of 1.15 or greater implies an increased risk of rejection.
What are the benefits of the Pleximmune™ test?
Determining whether rejection is likely is important in deciding whether the amount of anti-rejection medications is enough, whether these anti-rejection medications can be decreased further, or whether additional tests are needed to confirm whether rejection is already present or not. Knowledge about the likelihood of rejection can be combined with other clinical data by your healthcare provider to make clinical decisions.
How do I order the Pleximmune™ test?
The PleximmuneTM test must be ordered by your healthcare provider. The test requisition form is provided here. The completed form can be faxed to 412-224-2776. If there are any questions, please contact (855) PLE.XISION (753.9474) or 412-224-2504.
Is Pleximmune™ covered by insurance?
Plexision will bill your healthcare facility or your insurance plan as indicated on the requisition form. If there is no insurance coverage, Plexision patient assistance plans will assist with the cost of PleximmuneTM.
1. Patent 8759016
2. Transplantation. 2017 Jan; 101(1): 131–140. PMID: 26950712
3. Am J Transplant. 2009 Jan;9(1):179-91. PMID:18976293.
4. Surgery. 2009. Aug;146(2):166-73.PMID:19628070.
5. Pediatr Transplant. 2012 Feb;16(1):83-91. PMID: 22122074
6. Curr Opin Organ Transplant. 2011 Oct;16(5):515-21. PMID: 21844808
7. World J Transplant. 2014 March 24; 4(1): 30–39. PMID: 24669365
8. CLIA ID: 39D2042664
PleximmuneTM is FDA-approved